Compare Edwards Lifesciences Corporation Common Stock (EW) vs Honeywell Aerospace Inc. Common Stock (HONA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Honeywell Aerospace Inc. Common Stock — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $87.06 (market cap $49.15B), while Honeywell Aerospace Inc. Common Stock trades at $156.54 (market cap $50.14B). The key difference: Edwards Lifesciences Corporation Common Stock and Honeywell Aerospace Inc. Common Stock are close in size by market cap, and Edwards Lifesciences Corporation Common Stock is trading nearer its 52-week high, Honeywell Aerospace Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| EW | HONA | |
|---|---|---|
Market Cap | $49.15B | $50.14B |
Volume | 3,642,969 | 1,433,364 |
Sector | Health | Industrials |
52-Week High | $95.18 | $269.95 |
52-Week Low | $72.65 | $151.58 |
Enterprise Value | $45.60B | $64.96B |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Edwards Lifesciences (EW) trades at $85.27, down 1.3% with bearish technical signals. The company maintains strong fundamentals with 77.84% gross margins and recent FDA approval for the AUTUS pediatric valve. Despite a high P/E of 50.76, analysts project 20% upside to the $102.44 consensus target. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss.
EW faces valuation concerns with declining net income margins from 17.69% to 15.43% year-over-year. Technical resistance at $86-89 and negative cash flow trends present near-term challenges. However, institutional accumulation and zero sell ratings suggest long-term confidence in structural heart growth platforms.
HONA trades at $158.18, up 0.58% today, with neutral technical indicators showing support at $156 and resistance at $160. The company reported Q2 2026 EPS of $1.87, missing expectations of $2.07, while revenue grew to $17.40B in 2025. Analyst consensus remains mixed with a $211.25 price target, but multiple class action lawsuits filed in October 2026 create significant legal overhang.
HONA faces near-term headwinds from earnings miss and legal challenges, though strong cash flow generation and analyst price targets suggest long-term potential. Investors should weigh the 42.9% buy rating against litigation risks and declining profit margins projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Honeywell Aerospace Inc. Common Stock
Honeywell Aerospace Inc. is an aerospace and defense technology company, spun off from Honeywell in June 2026, that designs and supplies avionics, propulsion components (including auxiliary power units and engines), and connectivity systems for commercial, defense, and space aircraft.
Read more on HONA →
